Here are the DEF 14A proxy statements from Teladoc Health, Inc. (TDOC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow TDOC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TDOC filings page.
Teladoc Health is asking stockholders to vote at its 2026 virtual annual meeting on three main items: electing nine directors, an advisory Say‑on‑Pay vote on executive compensation, and ratifying Ernst & Young LLP as independent auditor for 2026. Only holders of record on March 26, 2026 may vote.
The Board is 89% independent, led by a separate independent chair, and operates through five committees, including Audit, Compensation, Nominating and Corporate Governance, and Quality of Care and Patient Safety. Two new independent directors joined in 2026, bringing average director tenure to six years and average age to 67.
For 2025, Teladoc reported $2.5 billion in total revenue, $281 million in adjusted EBITDA with an 11.1% margin, $781 million in cash and cash equivalents, and $458 million in international revenue, which grew 12%. Executive pay is highly performance‑based: equity and incentives represented 92.9% of the CEO’s target compensation and 83.7% for other named executives, and lower‑than‑target results led to below‑target payouts. The Board recommends voting FOR all management proposals.